newsfilter
← Latest News
GlobeNewswire·

Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Q1 2025 revenue of $22.1 million; GAAP basic EPS: $0.03Completed data collection and achieved database lock for the pivotal Phase 3 trial of Hydronidone in Chronic Hepatitis B ("CHB")-associated liver fibrosis; currently